Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
|
|
Reuters NewMedia - October 8, 2007
Writing in the journal Neurology, the researchers said their study also pointed to a way to measure this progressive brain damage when it does occur.
The AIDS drugs combinations, known as highly active antiretroviral therapy or HAART, suppress the virus but do not remove it completely from the body. Patients are not cured but their immune systems are not as badly damaged as untreated patients.
HIV can also attack the brain and nerves. Before HAART was available, about 20 percent of people with AIDS developed dementia. But not all of the drugs used in these mixtures get into the brain, so it was not clear how much they helped.
Dr. Asa Mellgren of Goteborg University in Sweden and colleagues studied 53 men and women infected with HIV. They tested their cerebrospinal fluid, then gave them HAART for one year.
Before treatment, 21 of the patients had high levels of a protein called neurofilament light protein, which was believed to point to brain damage.
After three months of taking HAART, those high levels of protein fell to normal levels in nearly half of the patients. After one year of treatment, only four people still had high levels of the protein, they reported.
All but one of the patients with normal levels remained normal for the year.
"This type of treatment appears to halt the neurodegenerative process caused by HIV," Mellgren said in a statement.
"This study confirms that neurofilament light protein serves as a useful marker in monitoring brain injury in people with HIV and in evaluating the effectiveness of HAART."
071008
RE071011
Copyright © 2007 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .